Rick Doblin - MDMA-assisted therapy for PTSD

MDMA-assisted therapy for PTSD is presented as a robust clinical intervention nearing regulatory approval. Clinical studies, specifically two successful Phase 3 trials, demonstrate that MDMA effectively reduces PTSD symptoms, including within populations struggling with chronic conditions and the dissociative subtype. The therapy protocol involves three dosing sessions interspersed with twelve non-drug psychotherapy sessions, which are essential for processing the breakthrough experiences prompted by the substance. Looking beyond the initial medicalization of MDMA, the Multidisciplinary Association for Psychedelic Studies (MAPS) aims to formalize training for 25,000 therapists by 2030 and establish thousands of specialized clinics worldwide. These efforts prioritize professionalizing psychedelic medicine while simultaneously exploring its potential for treating other conditions like schizophrenia and building support for global humanitarian projects.